Generation Bio to Present at the TD Cowen 45th Annual Health Care Conference

Rhea-AI Summary

Generation Bio (Nasdaq: GBIO), a biotechnology company focused on developing treatments for T cell-driven autoimmune diseases, has announced its participation in the upcoming TD Cowen 45th Annual Health Care Conference.

The company's president and CEO, Geoff McDonough, M.D., will deliver a presentation on Monday, March 3, 2025, at 9:10 a.m. ET in Boston. Investors and interested parties can access a live webcast of the presentation through the investor section of Generation Bio's website at investors.generationbio.com. The presentation recording will remain available for replay on the website for 30 days after the event.

News Market Reaction – GBIO

-1.02%

1 alert

-1.02% News Effect

On the day this news was published, GBIO declined 1.02%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:10 a.m. ET in Boston.

A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.  

About Generation Bio   

Generation Bio is a biotechnology company changing what's possible for people living with T cell-driven autoimmune diseases. The company is developing a new modality of therapeutics leveraging its T cell-selective cell-targeted lipid nanoparticle (ctLNP) to deliver siRNA in vivo, enabling modulation of T cell activity that causes inflammation and auto-reactive tissue destruction. By selectively modulating T cells that drive disease pathology, ctLNP-siRNA therapeutics could potently block target function with sequence-level specificity while sparing the broader immune system. This potent new modality is designed to reach targets that are poorly drugged by other approaches, opening a broad indication space of T cell-driven autoimmune diseases.

For more information, please visit www.generationbio.com.

Investors and Media Contact  
Maren Killackey  
Generation Bio  
mkillackey@generationbio.com  
857-371-4638  
  

FAQ

When is Generation Bio (GBIO) presenting at the TD Cowen Health Care Conference 2025?

Generation Bio will present at the TD Cowen Health Care Conference on Monday, March 3, 2025, at 9:10 a.m. ET in Boston.

How can investors watch Generation Bio's (GBIO) TD Cowen conference presentation?

Investors can watch the live webcast of the presentation through Generation Bio's investor website at investors.generationbio.com. A replay will be available for 30 days after the event.

What is the focus area of Generation Bio's (GBIO) research and development?

Generation Bio focuses on developing treatments for T cell-driven autoimmune diseases.

Who will represent Generation Bio (GBIO) at the TD Cowen Healthcare Conference 2025?

Geoff McDonough, M.D., president and chief executive officer of Generation Bio, will represent the company at the conference.